本文關(guān)鍵詞： 臨床路徑 臨床藥師 股骨頸骨折 藥學(xué)干預(yù) 疾病診斷相關(guān)組預(yù)付費制度　出處：《中國藥房》2017年23期 　論文類型：期刊論文

【摘要】：目的:探討在疾病診斷相關(guān)組預(yù)付費制度(DRGs-PPS)下的臨床藥師參與股骨頸骨折臨床路徑的實施效果,為促進(jìn)臨床合理用藥提供參考。方法:收集我院進(jìn)入臨床路徑的股骨頸骨折患者作為研究對象。2015年1-12月的患者為對照組,入徑52例,完成路徑41例;2016年1-12月的患者為觀察組,入徑58例,完成路徑46例。臨床藥師參與觀察組患者的臨床路徑實施,對臨床用藥進(jìn)行技術(shù)干預(yù)和行政干預(yù),對照組未進(jìn)行干預(yù)。觀察兩組患者住院時間、住院費用、藥品費用及不良反應(yīng)情況,并比較兩組患者預(yù)防用抗菌藥物、鎮(zhèn)痛藥、輔助用藥、抗骨質(zhì)疏松藥、抗凝藥等5類藥物的合理性。結(jié)果:臨床藥師參與觀察組臨床路徑實施后,兩組患者住院時間和不良反應(yīng)發(fā)生率比較,差異均無統(tǒng)計學(xué)意義(P0.05);觀察組患者的住院費用、藥品費用顯著低于對照組,差異均有統(tǒng)計學(xué)意義(P0.05)。觀察組患者預(yù)防用抗菌藥物的用藥時間和費用、鎮(zhèn)痛藥的用藥費用、輔助用藥的用藥時間顯著低/短于對照組,抗骨質(zhì)疏松藥用藥品種均顯著多于對照組,差異均有統(tǒng)計學(xué)意義(P0.05)。結(jié)論:在DRGs-PPS下,臨床藥師參與股骨頸骨折臨床路徑的實施,在一定程度規(guī)范了我院骨科5類藥物的用藥合理性,確保骨科臨床用藥安全、有效、經(jīng)濟(jì)。
[Abstract]:Objective: to investigate the effect of clinical pharmacists involved in the clinical pathway of femoral neck fracture under the DRGs-PPSs system. Methods: the patients with femoral neck fracture who entered the clinical path in our hospital were collected as the research object. The patients from January to December of 2015 served as the control group, 52 patients with the route and 41 patients with the complete route, and the patients from January to December of 2016 as the observation group, and the patients from January to December of 2016 as the observation group. The clinical pharmacists participated in the implementation of the clinical pathway of the patients in the observation group, and carried out technical and administrative intervention on the clinical medication, while the control group did not intervene. The duration of hospitalization and the cost of hospitalization were observed in the two groups. The cost of drugs and adverse reactions were compared between the two groups. The rationality of 5 kinds of drugs such as antimicrobial drugs, analgesic drugs, adjuvant drugs, anti-osteoporosis drugs and anticoagulant drugs were compared between the two groups. Results: after the clinical pharmacists participated in the implementation of the clinical pathway in the observation group, There was no significant difference in the length of stay and the incidence of adverse reactions between the two groups (P 0.05), while the hospitalization cost and drug cost in the observation group were significantly lower than those in the control group. The difference was statistically significant (P 0.05). The time and cost of prophylactic use of antimicrobial agents, the cost of analgesics and the time of adjuvant medication in the observation group were significantly lower than those in the control group. The variety of anti-osteoporosis drugs was significantly more than that of the control group (P 0.05). Conclusion: under DRGs-PPS, the clinical pharmacists are involved in the implementation of the clinical pathway of femoral neck fracture. To a certain extent, the rationality of the use of 5 kinds of drugs in orthopedic department of our hospital is standardized to ensure the safety, efficiency and economy of clinical use of orthopedic drugs.
【作者單位】： 北京懷柔醫(yī)院藥劑科;
【分類號】：R683
，

本文編號：1528470